On Friday, Chinese company Cansino Biologics Inc’s vaccine was approved by the Drug Regulatory Authority of Pakistan (DRAP), making it the fourth Covid-19 vaccine to be approved for emergency use by Pakistan.
Cansino Bio is the only vaccine for which Pakistan conducted a clinical trial, with around 18,000 volunteers participating from across the country.
As per data released by the Independent Data Monitoring Committee ( IDMC), the vaccine has a 100 percent efficacy rate in preventing severe disease and 74.48 percent in preventing symptomatic cases.
“The decision was taken considering the results of the trials. So far, four vaccines- Sinophram (China), Oxford-AstraZeneca (UK), Sputnik-V (Russia), and Cansino Bio (China)- have been registered. This will make it easy to arrange the vaccine for such a large population to create herd immunity,’’ Sajid Shah (Ministry of National Health Services spokesperson) confirmed the emergency use authorization of vaccine.
During the clinical trial of Cansino Bio at the University of Health Sciences 6,000 volunteers were vaccinated and only five percent of the volunteers developed a minor fever but not a single hospital admission was reported.
Meanwhile, the number of COVID-19 cases in the county reached 565,989 after 1,272 new cases were detected in the last 24 hours, according to the Ministry of National Health Services.
The views expressed in this article are the author’s own and do not necessarily reflect Propergaanda’s editorial stance.
Author’s email: firstname.lastname@example.org